Efficient recruitment in Alzheimer’s disease (AD) trials is challenging, and early use of sensitive biomarkers can reduce screen failures and costs. We evaluated an MRI-based machine learning model, previously trained to classify AD, FTD, normal controls, and other dementias, as a pre-screening tool using A4 Study data.
Read more